Laurens van Zandvoort

Showing 1-3 of 3 articles

Coronary interventions

Validation of 3-Dimensional Quantitative Coronary Angiography based software to calculate Fractional Flow Reserve: Fast Assessment of STenosis severity (FAST)-study

Masdjedi K, van Zandvoort L, Balbi MM, Gijsen F, Ligthart J, Rutten M, E Lemmert ME, Wilschut J, Diletti R, de Jaegere P, Zijlstra F, Van Mieghem N, Daemen J

May 14, 2019 | 10.4244/EIJ-D-19-00466

Coronary interventions

Intravascular ultrasound findings of the Fantom sirolimus-eluting bioresorbable scaffold at six- and nine-month follow-up: the FANTOM II study

van Zandvoort L, Dudek D, Weber-Albers J, Abizaid A, Christiansen E, Muller D, Kochman J, Kołtowski Ł, Flensted Lassen J, Wojdyla R, Wykrzykowska J, Onuma Y, Daemen J

December 7, 2018 | 10.4244/EIJ-D-18-00491

Interventions for hypertension

Serial quantitative magnetic resonance angiography follow-up of renal artery dimensions following treatment by four different renal denervation systems

van Zandvoort L, van Kranenburg M, Karanasos A, Van Mieghem N, Ouhlous M, van Geuns R, van Domburg R, Daemen J

April 7, 2017

1

Latest news

CTOs, next-day discharge after TAVI, ViV, cerebral embolic protection, TMVR

Ahead of Print: Coronary Artery Thrombosis in COVID-19

Coronary collaterals, the natural grafts of CTO lesions

TICAKOREA, PEPCAD NSTEMI, CROSS-AMI, PARTNER-2A 5 years, and more

(The Trials book is supported by Biotronik)

Guidance Papers

Guidelines, consensus & position papers

Intravascular ultrasound in PCI for in-stent CTO: guidance for long-term success

JM De la Torre Hernandez

This Week's JAA's: Real-world Use of the Evolut PRO Valve...

Valvular disease